Maria Rangel to Middle Aged
This is a "connection" page, showing publications Maria Rangel has written about Middle Aged.
Connection Strength
0.198
-
Rangel MO, Kaplan R, Daviglus M, Schneiderman N, Hurwitz BE, Cai J, Gonzalez F, Kitzman D, Kansal M, Rodriguez CJ. Estimation of Incident Heart Failure Risk among US Hispanics/Latinos Using a Validated Echocardiographic Risk-Stratification Index: the Echocardiographic Study of Latinos. J Card Fail. 2018 09; 24(9):622-624.
Score: 0.062
-
Rangel MO, Morales Demori R, Voll ST, Wassouf M, Dick R, Doukky R. Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials. J Nucl Cardiol. 2015 Oct; 22(5):1008-18.
Score: 0.048
-
Rangel MO, Demori RM, Doukky R. Age and gender as predictors of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: a substudy of the ASSUAGE trial. Am J Ther. 2013 Nov-Dec; 20(6):622-9.
Score: 0.045
-
Doukky R, Hayes K, Frogge N, Balakrishnan G, Dontaraju VS, Rangel MO, Golzar Y, Garcia-Sayan E, Hendel RC. Impact of appropriate use on the prognostic value of single-photon emission computed tomography myocardial perfusion imaging. Circulation. 2013 Oct 08; 128(15):1634-43.
Score: 0.011
-
Doukky R, Frogge N, Balakrishnan G, Hayes K, Collado FM, Rangel MO, Trohman RG, Hendel RC. The prognostic value of cardiac SPECT performed at the primary care physician's office. J Nucl Cardiol. 2013 Aug; 20(4):519-28.
Score: 0.011
-
Doukky R, Rangel MO, Wassouf M, Dick R, Alqaid A, Morales Demori R. The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation. J Nucl Cardiol. 2013 Apr; 20(2):205-13.
Score: 0.010
-
Doukky R, Rangel MO, Dick R, Wassouf M, Alqaid A, Margeta B. Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial. Int J Cardiovasc Imaging. 2013 Jun; 29(5):1029-37.
Score: 0.010